

Amendments to the Claims:

Claims 1 - 43 (Canceled).

44. (Previously presented) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO: 2);
- (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO: 2), lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258.

45. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2).

46. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2) lacking its associated signal peptide.

Claims 47-48 (Canceled).

49. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258.

Claims 50 - 51 (Canceled)

52. (Currently amended) An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);
- (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or,
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258;

~~wherein said polypeptide is associated with the formation or growth of lung or colon tumor~~ inhibits VEGF stimulated proliferation of endothelial cells.

53. (Currently amended) The isolated polypeptide of Claim 52 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);
- (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258;

~~wherein said polypeptide is associated with the formation or growth of lung or colon tumor~~ inhibits VEGF stimulated proliferation of endothelial cells.

54. (Currently amended) The isolated polypeptide of Claim 52 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);
- (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258;

~~wherein said polypeptide is associated with the formation or growth of lung or colon tumor~~ inhibits VEGF stimulated proliferation of endothelial cells.

55. (Currently amended) The isolated polypeptide of Claim 52 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);
- (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258;

wherein said polypeptide ~~is associated with the formation or growth of lung or colon tumor~~ inhibits VEGF stimulated proliferation of endothelial cells.

56. (Currently amended) The isolated polypeptide of Claim 52 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);
- (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209258;

wherein said polypeptide ~~is associated with the formation or growth of lung or colon tumor~~ inhibits VEGF stimulated proliferation of endothelial cells.

57. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 44 fused to a heterologous polypeptide.

58. (Previously presented) The chimeric polypeptide of Claim 57, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

59. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 52 fused to a heterologous polypeptide.

60. (Previously presented) The chimeric polypeptide of Claim 59, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin